Array Technologies Inc (ARRY)

[Basil22]

Amazing company with a bright future.
Great pipeline.

[girlfriend]

https://ih.advfn.com/p.php?pid=nmona&article=78301701&symbol=ARRY

[DCALongRun]

Market makers have finished pushing it down.


Guggenheim had a upgrade on Monday.
https://xnewspress.com/2018/09/18/array-biopharma-arry-now-covered-by-analysts-at-guggenheim.html

[girlfriend]

ARRY up 5.5% whats going on here don't see any news....

[DCALongRun]

Looks like sell off caused by dilution....

https://www.sec.gov/Archives/edgar/data/1100412/000104746918003600/a2235591z424b5.htm

[Beerworld]

It had been bought up before. Typical sell the news. Should rise, it's good news for their pipeline.

[north40000]

Didn't do much for share price today:

https://ih.advfn.com/p.php?pid=nmona&article=77756290

"BOULDER, Colo., June 27, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI™ capsules in combination with MEKTOVI® tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for the treatment of patients with wild-type BRAF melanoma....[more]"

[Axeman]

In at 16.98 for 246. Watch for 52 week high break. Catalyst events fueling

[trading_cyclist]

sure you did.

[Hotrodder1]

I can’t believe it! Just finished filling out paperwork on my claim in the class action Aria lawsuit. I receive another 60k!

[stock442]

Good news as they have agreement with array Biopharma.

[stock442]

https://www.businesswire.com/news/home/20180215005529/en/Selumetinib-Granted-Orphan-Drug-Designation-U.S.-FDA

[northern vortex]

ARRY sues AZN for royalties

https://www.reuters.com/article/us-astrazeneca-array-biopharma/astrazeneca-is-sued-by-array-biopharma-over-cancer-drug-royalties-idUSKBN1FL6O6

[Hotrodder1]

I’m glad I don’t have to do any EOY selling!

[stockguard]

Looks like pricing between $9.35-$10.00

[rwwine]

Excellent point!! Where do you think this will settle down at on PPS?

TIA

[stockguard]

This is why the stock had a hard time breaking out further on all the upgrades and great PR`s the past few days.
Wait to buy again after the pricing....

Press Release: Array BioPharma Announces Proposed Public Offering of Common Stock

4:02 pm ET September 13, 2017 (Dow Jones) Print
Array BioPharma Announces Proposed Public Offering of Common Stock

PR Newswire

BOULDER, Colo., Sept. 13, 2017

BOULDER, Colo., Sept. 13, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common stock. Array BioPharma also intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Array BioPharma.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the proposed offering. Piper Jaffray & Co. is also acting as a bookrunner for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The shares are being offered by Array BioPharma pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (SEC) and became effective. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC, and will be available on the SEC's website at www.sec.gov.

When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, telephone: [phone]; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York, 11717, Attn: Prospectus Department, telephone: [phone]; or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department, telephone: [phone].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the proposed public offering. These statements involve significant risks and uncertainties, including those discussed in the preliminary prospectus supplement related to the offering and in our most recent annual report filed on Form 10-K. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. There can be no assurance that Array BioPharma will be able to complete the offering. We are providing this information as of September 13, 2017. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

CONTACT: Tricia Haugeto, Array BioPharma

[phone]

[e-mail]

[stockguard]

Array BioPharma Is Maintained at Overweight by Cantor Fitzgerald
9:33 am ET September 11, 2017 (Dow Jones) Dow Jones Newswires
September 11, 2017 09:33 ET (13:33 GMT)DJ Array BioPharma Price Target Raised to $15.00/Share From $13.00 by Cantor Fitzgerald(END) Dow Jones Newswires
Ratings actions from Benzinga: http://www.benzinga.com/stock/ARRY/ratings

[stockguard]

We are reiterating our Outperform rating on shares of ARRY and
increasing our price target to $28 following review of BEACON data
in mCRC for encorafenib + binimetinib. Results are better than
expected, should support a new standard of care for BRAF colorectal
cancer and should conservatively support peak sales of $2.2B, not
reflected in current valuation.
? The Wells Fargo Securities biotechnology team attended an investor
event hosted by Array BioPharma (ARRY) at the European Society
for Medical Oncology (ESMO) over the weekend in Madrid, Spain.
Focus of the meeting was on a 30 patient lead-in phase of the
BEACON phase 3 study of ERBITUX + encorafenib +/- binimetinib
(EEB) in 29 patients with V600E BRAF+ melanoma and expert
feedback on the results.
? Results were better than expected with 41% overall response rate
(ORR), 52% stable disease rate, and 93% disease control rate
(DCR) , and 100% disease control rate (DCR) in 27 evaluable
patients with 2nd-line+ treatment. For 2nd line patients results were
particularly strong with 57% ORR. Progression free survival (PFS)
data was not yet mature, but 12 of 29 patients had disease control
duration beyond 6 months, and expert feedback suggested that it
would be statistically improbable for PFS to be less than 6 months.
? Results are well beyond ORR for standard of care of 4% to 6%, and
21% ORR for other RAF/MEK/ERBITUX combinations. With PFS
potentially beyond 6 months, we would note standard of care PFS of
just 2 months, and overall survival (OS) of only 6 months. Expert
feedback at the meeting suggests that ERBITUX + encorafenib +
binimetinib (EEB) data are transformational, and should quickly
become a standard of care 2nd-line and likely migrate quickly to
frontline use. Based on expert feedback we expect BEACON to enroll
very rapidly with data likely well before our current 3Q19 estimate.

[stockguard]

Array BioPharma: Data Updates Point To Continued Upside

https://seekingalpha.com/article/4105699-array-biopharma-data-updates-point-continued-upside

[stockguard]

Harry Boxer
After forming a base at $7.50 within a rising channel since April, price finally broke out above the $9 lateral resistance level on Wednesday on no apparent news. If price can rally above the $10.30 zone, next targets are $12 and $13.50, with $15 targeted in the longer term.

https://www.thetechtrader.com/chartsoftheday/ARRY-COOL-ONCE-TRTN-201708231970.html

[stockguard]

Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress

Sat September 9, 2017 9:30 AM|PR Newswire|About: ARRY

https://seekingalpha.com/pr/16935982-phase-3-columbus-part-2-results-braf-mutant-melanoma-presented-european-society-medical

[stockguard]

Array Bio's binimetinib and encorafenib show encouraging treatment effect in initial phase of late-stage study in treatment-resistant colorectal cancer.

[yankees7]

Array Bio's binimetinib and encorafenib show encouraging treatment effect in initial phase of late-stage study in treatment-resistant colorectal cancer; shares ahead 17%

[Awl416]

T1

[sonicty28]

Why is ARRY running lately?

[Inoviorulez]

https://seekingalpha.com/article/4101681-array-biopharma-one-small-cap-biotech-everyones-portfolio

[INTL]

ARRY 7/17 Looking very favorable for approval. Bullish
http://www.insidermonkey.com/blog/what-are-array-biopharma-inc-arrys-chances-of-pdufa-success-472106/

[INTL]

ARRY orphan drug fast track date set for FDA 7/17 for pudfa. Bullish

[DCALongRun]

We are still out there. I made $1500 flipping this on reversal of selloff back in May. I also have some shares for long term investment in both taxable and retirement accounts.

[Craig305]

Check out the posts on StockTwits

[PositiveThoughts]

you and me both. Looks like everyone has abandoned this stock. You can hear the crickets on this board.

[Chuck87]

Red with news. Don't understand that one.

[ClayTrader]

* * $ARRY Video Chart 05-10-17 * *

Link to Video - click here to watch the technical chart video

[island man]

9.24 high today nice chunk of change made here.....

[nferna]

I love the timing of the PR last night. Nobody was expecting any news until market close today. Caught the market, and especially the shorts off guard, in the best possible way.

[DCALongRun]

Weekly chart 30 minute time frame. Looks like a bottom has been put in. Higher highs and higher lows.

[island man]

DCA it hit 8.20 @ 16:04 nice move on the news now the catalyst for Wednesday would be beating the street numbers and pop back over double digits.....

[buysell101]

Thanks for the update.

[DCALongRun]

They announced positive top line results for part 2 of phase 3 Columbus study.

[buysell101]

What happened in After hours?

[DCALongRun]

I picked up a bunch of shares this morning. Glad I did. Wow. After hours prices its at 8.10. Closed at 7.02.

[island man]

Let's see if they can beat a .16 loss and have a greater revenue than 47 million.

[island man]

good point Would like to see some insiders stepping up to the plate even to buy a few thousand shares.I just researched that approximately 162 million shares are owned by institutions.I wonder if they daytrade....

[DCALongRun]

I am staying out until I get technical signal for bullish trend. Good news comes out and pps goes negative trading under 7. Sadly the shorts are in full control of this stock. Remember last February this stock was trading very low. I sat as a bag holder when I bought at $4 in 2015, not any more.

[island man]

ARRY is getting "hairy investment" they need to have decent numbers on the 10th to get some life back in this stock

[DCALongRun]

ARRY is now below 200 day moving average.

[ClayTrader]

* * $ARRY Video Chart 05-02-17 * *

Link to Video - click here to watch the technical chart video

[XenaLives]

Roughly 200 sma...

But VBP price support is around $6.70.

[4starman]

Yea. Looks like it might have bottomed.